328918-80-5

Upstream product

• 1122-91-4 4-bromo-benzaldehyde 
• 135636-66-7 butane-2,3-dione mono-oxime 
• 57-71-6 2,3-Butanedione monoxime 

Downstream Products

• 328918-81-6 2-(4-bromophenyl)-4-(chloromethyl)-5-methyl-1,3-oxazole 
• 328918-83-8 [2-(4-bromophenyl)-5-methyloxazole-4-yl]-acetonitrile 
• 328918-84-9 2-(4-bromophenyl)-5-methyl-4-oxazoleethanol 
• 328918-82-7 2-(4-bromophenyl)-5-methyl-4-oxazoleacetic acid 
• 328918-85-0 2-(2-(biphenyl-4-yl)-5-methyloxazol-4-yl)ethanol 
• 328918-86-1 toluene-4-sulfonic acid 2-(2-biphenyl-4-yl-5-methyloxazol-4-yl)ethyl ester 
• 401468-89-1 3-{4-[2-(2-Biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-(4-tert-butylphenoxy)-propionic acid 
• 853260-43-2 3-{4-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-(4-tert-butyl-phenoxy)-2-methyl-propionic acid ethyl ester 
• 328918-91-8 2-(4-bromophenyl)-5-methyl-4-vinyloxazole 
• 328918-89-4 toluene-4-sulfonic acid 2-[2-(4-bromophenyl)-5-methyloxazol-4-yl]ethyl ester 
• 328918-90-7 2-(4-{2-[2-(4-bromophenyl)-5-methyloxazol-4-yl]ethoxy}phenoxy)-2-methylpropionic acid ethyl ester 
• 328918-26-9 2-{4-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenoxy}-2-methyl-propionic acid 
• 328918-88-3 2-{4-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenoxy}-2-methyl-propionic acid ethyl ester 

Relevant academic research and scientific papers

1,3-Oxazole-isoniazid hybrids: Synthesis, antitubercular activity, and their docking studies

A series of novel N′-([2-aryl-5-methyl-1,3-oxazole-4-yl]methylene)isonicotino/nicotino hydrazides 10a-l were prepared by the condensation reaction of 2-aryl-5-methyl-1,3-oxazole-4-carbaldehydes 8a-f with the corresponding isonicotino/nicotino hydrazides 9

Preparation of 2-(1-chloroalkyl)-4,5-dimethyloxazoles and (E)2-alkenyl-4,5-dimethyloxazoles

2-(1-Chloroalkyl)-4,5-dimethyloxazoles were prepared in 84-91% yields by simultaneous reduction and regioselective chlorination of the corresponding unstable N-oxides with POCl3 or SOCl2. Dehydrochlorination of 2-(1-chloroalkyl)-4,5-

HETEROCYCLIC COMPOUNDS AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS, USEFUL FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS MODULATED BY A PPAR

The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists

Novel compounds that are modulators of PPAR receptors, and pharmaceutically acceptable salts, solvates and hydrates thereof, processes for making the compounds, pharmaceutical compositions containing the compounds, or pharmaceutically acceptable salts, solvates and hydrates thereof.

Conversion of human-selective PPARα agonists to human/mouse dual agonists: A molecular modeling analysis

To understand the species selectivity in a series of α-methyl- α-phenoxy carboxylic acid PPARα/γ dual agonists (1-11), structure-based molecular modeling was carried out in the ligand binding pockets of both human and mouse PPARα. This study suggested that interaction of both 4-phenoxy and phenyloxazole substituents of these ligands with F272 and M279 in mouse PPARα leads to the species-specific divergence in ligand binding. Insights obtained in the molecular modeling studies of these key interactions resulted in the ability to convert a human-selective PPARα agonist to a human and mouse dual agonist within the same platform.

Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists

Compounds represented by the following (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubsituted or substituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is H, alkyl or haloalkyl. R4 is H, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

Modulators of peroxisome proliferator activated receptors

The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented b

Design and synthesis of 2-methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy}propionic acids: A new class of dual PPARα/γ agonists

Propionic acid derivative 8, which was designed and synthesized based on putative pharmacophores of known PPARγ- and PPARα-selective compounds, exhibits potent dual PPARα/γ agonist activity as demonstrated by in vitro binding and dose overlap in the newly